To meet the increasing demand in Asia, SCHOTT invested 75 million euros (approx. INR 660 Cr) over the last three years to expand its pharma glass production in India. The Gujarat-based facility is the company’s manufacturing hub for borosilicate glass tubing, a high-quality material that is converted to pharmaceutical containers, such as vials, ampoules, or syringes, to store life-saving drugs.
This expansion contributes to the Indian government’s vision of further strengthening India as a global pharmaceutical hub, while also supporting Germany’s commitment to increasingly invest in India – as recently agreed upon by Chancellor Olaf Scholz and Indian Prime Minister Narendra Modi.
At the official opening event , local government officials, business unit executives, and pharma industry representatives celebrated the start of a new production of FIOLAX® amber pharmaceutical glass tubing. With this move, manufacturers of drug containment solutions in the region can now receive SCHOTT’s complete portfolio of pharmaceutical glass tubing produced in India. Amber glass is used to store light-sensitive medications such as antibiotics or chemotherapeutic agents. The local production will also improve availability, planning reliability, and cost efficiency for pharmaceutical converters.
“As part of our strategy to manufacture close to our customers, we are enabling their growth plans by ensuring a sufficient regional supply of high-quality pharmaceutical glass tubing,” says Dr. Patrick Markschläger, Executive Vice President of SCHOTT’s Business Unit Tubing. Since breaking ground for construction of the expansion in 2021, the company has achieved its first milestone: “We have been a reliable partner for the healthcare industry in India for decades and are pleased to expand our local footprint even further. We would like to thank the local authorities and our partners for making this project a success,” explains Pawan Shukla, Managing Director of SCHOTT Glass India.